30-day average of 15 articles · scale −100 to +100
Across 15 scored articles from Oct 16 to Nov 14, 2026 (UTC),
the average sentiment of Elevance Health news is Bullish (+55)
on a scale from −100 to +100.
That is up 19 points from the previous 30 days (+36).
📈 ELV shares up 33.6% in 12 months despite earnings valuation questions.
⚠️ Elevated behavioral health utilization may limit scaling of cost savings.
Somewhat Bullish +45
Elevance Health (ELV) Stock Looks Reasonable After Raised Earnings Outlook
AI-generated analysis
Key insights
📈 Elevance Health shares have gained 33.6% over the past 12 months, raising questions about whether current earnings fully support the price advance.
📉 The company trades at a P/E ratio of approximately 18.1x, which is well below the broader Healthcare sector average of 25.3x and peer group averages near 31.4x.
💰 Management has lifted its longer-term earnings outlook and flagged potential improvements in Medicaid margins to support future profit growth.
🛡️ Carelon's complex behavioral care programs have shown around 10% cost savings and reduced inpatient admissions, supporting value-based relationships.
🏥 Expansion of home-based CareBridge services into new markets aims to deepen revenue from health services and support margin resilience.
⚠️ Persistent elevated utilization in behavioral health, specialty pharmacy, and emergency departments suggests cost savings may not scale fast enough across the wider book.
📊 Analyst consensus narratives on Simply Wall St currently split between a bullish view of 9% undervaluation and a bearish view of roughly fair value.
⚖️ Despite a recent lawsuit over alleged fraudulent billing, the market continues to price Elevance Health at a discount to sector norms.
📈 Bullish signals
💰Management has lifted its longer-term earnings outlook, signaling confidence in future profit growth and operational efficiency.
📉The stock trades at a P/E ratio of approximately 18.1x, which is significantly lower than the broader Healthcare sector average of 25.3x and peer group averages near 31.4x, suggesting potential undervaluation.
🛡️Carelon's behavioral care programs have demonstrated around 10% cost savings and reduced inpatient admissions, indicating strong operational performance.
🏥Expansion of home-based CareBridge services into new markets is expected to deepen value-based relationships and support future margin resilience.
📉 Risk factors
⚠️Persistent elevated utilization in behavioral health, specialty pharmacy, and emergency departments suggests that projected medical cost savings may not scale fast enough across the wider book.
⚖️A recent lawsuit over alleged fraudulent billing has put a spotlight on the company's risk controls, though the market currently prices the shares at a discount to sector norms.
Article
Elevance Health (ELV) shares have appreciated 33.6% over the past year, prompting investors to assess whether current earnings power justifies the valuation. The company recently raised its longer-term earnings outlook and highlighted potential improvements in Medicaid margins, which could enhance the durability and predictability of future profit growth within an earnings-based valuation framework.
Analysts covering Elevance Health are currently divided on the stock's fair value. Simply Wall St analysis suggests a bullish case where the stock is 9% undervalued, driven by expansion in Carelon's behavioral care programs that have demonstrated approximately 10% cost savings and reduced inpatient admissions. These initiatives aim to deepen value-based relationships and support margin resilience.
Conversely, a bearish perspective views Elevance Health as roughly fairly valued, citing concerns that persistent elevated utilization in behavioral health, specialty pharmacy, and emergency departments may prevent the projected medical cost savings from scaling effectively across the wider book of business. Despite these mixed analyst views, the stock trades at approximately 18.1x earnings, which is significantly lower than the broader Healthcare sector average of 25.3x and peer group averages near 31.4x.
Sector and industry come from company profile data. Sentiment is the AI score of the news articles on this page, averaged per day. Not investment advice.
MCH Advisory Research maintains a HOLD rating on Elevance Health (ELV) with a 12-month probability-weighted target price of $371, representing an -8% downside from the current spot price of $402. The firm's triangulated fair value sits at $326 (-19%), driven by a conservative intrinsic DCF anchor that values the stock at $314 per share. This valuation assumes a terminal multiple of 12x FCF and a WACC of 8.5%, reflecting the market's view that ELV trades rich relative to its cash-flow generation capabilities.
The core thesis hinges on the sustainability of Elevance's gross margins, which explain 73% of the Monte Carlo outcome variance. The company operates with a thin operating margin near 3.6% on a massive premium base, making it highly sensitive to medical cost trends and Medicaid redeterminations that strip lower-cost members from the risk pool. Analysts note that while management has been unusually upbeat in recent quarters, the balance sheet carries net debt of approximately $22.2B, limiting the ability to use buybacks to cushion earnings compression.
The report identifies a structural downside risk where two consecutive prints of an elevated benefit-expense ratio could compress margins significantly and trigger a multiple de-rating. Conversely, upside depends on care-services mix improvements and Medicare Advantage margin recovery lifting both earnings and the valuation multiple. The scenario tree spans a bear case of $159 under regulatory reform pressures to a bull case of $668 if margins recover, but the probability-weighted blend remains below current levels.
📉 MCH Advisory rates ELV HOLD with $371 target price (-8% downside).
💰 Fair value anchored at $326 via conservative DCF model ($314/share).
📊 Gross margin drives 73% of Monte Carlo variance for future performance.
⚠️ Thin 3.6% operating margin creates high sensitivity to medical cost trends.
🏦 $22.2B net debt limits buybacks against potential earnings compression risks.
📉 MCH Advisory Research rates Elevance Health (ELV) as HOLD with a 12-month target price of $371, implying an -8% downside from the current spot price of $402.
💰 The firm's triangulated fair value is $326 (-19%), anchored by a conservative intrinsic DCF of $314/share using a 12x terminal FCF multiple and 8.5% WACC.
📊 Gross margin explains 73% of the Monte Carlo outcome variance, making it the single most critical variable for the stock's future performance.
⚠️ The company operates with a thin operating margin near 3.6% on a large premium base, creating high sensitivity to medical cost trends and Medicaid redeterminations.
🏦 Elevance carries net debt of approximately $22.2B, which limits the capacity for buybacks to offset potential earnings compression or margin deterioration.
📉 The highest-probability bear mechanism is the base path failing due to sustained medical cost spikes rather than a rare tail event.
🔍 Management tone has been unusually upbeat (+0.69 vs analyst floor), triggering an elevated disconfirmation watch flag for investors.
📈 The scenario tree ranges from a structural downside of $159 under reform pressures to a bull case of $668 if margins recover and the stock re-rates.
📉 Current valuation implies 14.8x consensus forward EPS, compared to a house DCF terminal multiple of 12.0x and a peer median P/E of 19.7x.
🛡️ The narrow moat relies on Blue Cross Blue Shield licensed scale and Carelon services, but the business remains politically exposed with capped MLR limits.
Bullish Signals
Narrow moat from BCBS scale and Carelon growth.
Trades at discount to peers, implying multiple expansion.
Risk Factors
Stock trades 19% rich vs. DCF anchor.
Medical cost spike risks earnings severely.
$22.2B net debt limits buybacks and adds risk.
Cash flow converts at only 76% of income.
Medicaid redeterminations strip members and pressure margins.
Bullish Signals
Elevance Health possesses a narrow moat supported by Blue Cross Blue Shield licensed scale, regulated membership relationships, and a growing Carelon services arm.
The company trades at a discount to managed-care peer medians on an EV/Revenue basis, implying potential multiple expansion if growth persists.
Risk Factors
The stock is trading rich relative to the house DCF anchor (-19%), which assumes a conservative terminal multiple of 12x FCF and a WACC of 8.5%.
A sustained medical cost trend spike is identified as the single most damaging risk, capable of pushing earnings toward the cost-trend path without structural reform.
The balance sheet carries net debt of ~$22.2B, adding financing sensitivity and limiting buyback capacity to cushion margin compression.
Operating cash flow has converted at only 76% of net income, indicating reserve pressure rather than strong earnings quality timing.
Medicaid redeterminations continue to strip lower-cost members from the risk pool while rate updates lag actual utilization, pressuring margins.
Elevance Health (ELV) shares have rallied approximately 33.6% over the past year to a price of roughly US$410.95, prompting an analysis of whether the current valuation aligns with the company's earnings power. Management has reaffirmed its 2026 earnings and cost guidance, signaling continued commitment to profitability and expense discipline despite the recent stock appreciation.
Valuation metrics indicate that Elevance Health trades at a P/E ratio of approximately 18.0x, which represents a discount compared to the broader Healthcare sector average of 24.0x and its peer group average near 26.8x. This pricing gap suggests the market is applying a more cautious multiple to the insurer relative to similar businesses, even as management maintains confident messaging regarding future profitability.
Analyst narratives from Simply Wall St present a split view on the stock's fair value. The bull case argues that Elevance Health is 8% undervalued due to aggressive leveraging of advanced analytics, digitization, and AI-enabled tools designed to streamline clinical workflows and reduce fraud. Conversely, the bear case suggests the stock is roughly fairly valued, citing risks from elevated costs in government-backed plans and margin compression associated with a greater reliance on value-based care models.
⚠️ ELV shares gained 33.6% YTD, trading at US$410.95.
💰 ELV trades at 18.0x P/E, below sector and peer averages.
📅 Management reaffirmed 2026 earnings targets and cost discipline.
🤖 AI and analytics streamline workflows to reduce fraud.
⚠️ Government plan costs could compress margins despite improvements.
📈 Elevance Health shares have gained 33.6% over the past year, trading at approximately US$410.95.
💰 The company trades at a P/E ratio of 18.0x, which is below the Healthcare sector average of 24.0x and peer group average of 26.8x.
📅 Management has reaffirmed its 2026 earnings targets and cost discipline guidance.
🤖 The bull case highlights the use of advanced analytics, digitization, and AI to streamline clinical workflows and reduce fraud.
⚠️ The bear case warns that elevated costs in government-backed plans could compress margins despite operational improvements.
📊 Analyst narratives suggest Elevance Health is either 8% undervalued or roughly fairly valued depending on the growth path assumed.
Bullish Signals
Management reaffirmed 2026 earnings and cost guidance.
Leveraging AI to streamline workflows and cut costs.
Risk Factors
Govt plan costs may compress margins.
Value-based care reliance risks margins.
Bullish Signals
Management has reaffirmed its 2026 earnings and cost guidance, signaling confidence in future profitability and expense control.
The company is aggressively leveraging advanced analytics, digitization, and AI-enabled tools to streamline clinical workflows, automate processes, reduce fraud, and improve cost management.
Risk Factors
Elevated costs in government-backed plans could compress margins despite the company's operational improvements and diversification strategies.
Greater reliance on value-based care models presents a risk of margin compression even as the insurer pursues operational efficiency.
Elevance Health shares traded around USD 414 on September 18, 2026, following a series of analyst price target revisions that reflect mixed but generally constructive sentiment. While RBC Capital lowered its target to USD 424 citing caution, major firms like TD Cowen, Truist Securities, and Wells Fargo raised or maintained targets between USD 465 and USD 492, signaling confidence in the company's earnings trajectory and cash generation capabilities.
The stock has delivered a one-month return of 4.6 percent, trading at approximately 18 times forward earnings with a dividend yield of 1.66 percent. Fundamentally, Elevance Health generates an annualized revenue base of USD 198.7 billion and has achieved roughly 26 percent return on invested capital over the past five years, demonstrating robust capital allocation and efficient cost management across its large membership base.
Analysts highlight that while the company's strong fundamentals support a balanced growth-and-income profile, investors must weigh sector-specific risks including regulatory changes to Medicare and Medicaid plans, as well as competitive pressure on premiums. The consensus view suggests that if Elevance Health can maintain its historical earnings-per-share growth rate of 7.2 percent annually, the stock remains supported by institutional demand despite macroeconomic uncertainties.
📈 Elevance Health trades near USD 414 with a market cap of roughly USD 89.9 billion.
📊 Analyst price targets range from USD 424 to USD 492, with major firms raising targets above current levels.
💰 The company generates an annualized revenue base of USD 198.7 billion for provider negotiations.
📈 Earnings per share grew approximately 7.2 percent annually over the past five years.
⚠️ Regulatory changes and rising medical costs could compress margins if pricing fails to offset increases.
📈 Elevance Health shares trade near USD 414 with a market capitalization of roughly USD 89.9 billion as of September 18, 2026.
📊 Analyst price targets range from USD 424 to USD 492, with major firms like TD Cowen and Wells Fargo raising targets above current levels.
💰 The company generates an annualized revenue base of USD 198.7 billion, providing significant bargaining power in provider negotiations.
📈 Earnings per share have grown by approximately 7.2 percent annually over the past five years, outpacing peer-group averages.
🏦 Return on invested capital stands at roughly 26 percent, indicating robust capital allocation and efficient use of shareholder funds.
📉 The stock trades at a price-to-earnings ratio of around 18.34 times forward earnings, reflecting a mid-teens valuation.
💸 Elevance Health offers a dividend yield of about 1.66 percent, appealing to long-term investors seeking income potential.
📉 The stock has posted a one-month return of 4.6 percent, placing it among surging stocks on various watchlists.
⚠️ Analysts note that the managed-care sector faces risks from regulatory changes to Medicare and Medicaid reimbursement structures.
⚠️ Competitive dynamics and rising medical costs could compress margins if pricing fails to fully offset these increases.
Bullish Signals
Analysts maintain Buy ratings with price targets from $465 to $492.
Stock returned 4.6% in one month showing positive momentum.
EPS grew 7.2% annually over the past five years.
Return on invested capital is roughly 26 percent.
Revenue base of $198.7 billion aids reimbursement negotiations.
Risk Factors
RBC lowered price target to USD 424 from USD 439.
Managed-care sector faces regulatory and policy risks.
Rising costs and competition could compress margins.
Bullish Signals
Major analyst firms including TD Cowen, Truist Securities, and Wells Fargo have raised or maintained Buy/Overweight ratings with price targets ranging from USD 465 to USD 492.
The company has delivered a one-month stock return of 4.6 percent, indicating sustained positive momentum beyond single-session moves.
Earnings per share have grown by approximately 7.2 percent annually over the past five years, demonstrating consistent bottom-line progress.
Return on invested capital is cited at roughly 26 percent, reflecting robust capital allocation and efficient use of shareholder funds.
The company generates a massive annualized revenue base of USD 198.7 billion, providing considerable bargaining power when negotiating reimbursement rates.
Risk Factors
RBC Capital lowered its price target to USD 424 from USD 439, signaling a slightly more cautious stance despite maintaining a Sector Perform rating.
The managed-care sector is heavily exposed to regulatory changes and public policy decisions around Medicare, Medicaid, and individual marketplace plans.
Rising medical costs combined with competitive pressure on premiums could compress margins if pricing does not fully offset these increases.
Elevance Health (ELV) is currently trading at $419.17 as of September 15, 2026, with technical indicators showing the stock above its 50-day average and an RSI in neutral territory. Financial analysts maintain a consensus price target of $457.00, representing a fair value approximately 9% higher than the current market price, supported by a majority of Buy or Overweight ratings from Wall Street.
Operational performance highlights include a recent history of exceeding earnings per share (EPS) estimates, with the most recent quarter to June 2026 showing a beat of 19.97%. However, revenue estimates for the current and next quarters project a year-over-year decline of approximately 2.00%, which lags behind the broader sector's positive growth trajectory.
Insider trading activity presents a mixed but slightly bullish signal, with insiders purchasing $5.1 million worth of stock compared to $3.7 million in sales over the reporting period. Long-term simulations by CleaRank project significant potential growth, estimating a base case value near $615 by 2030 and a bull case reaching $92,933 for a $10,000 investment by 2036, though these are statistical projections rather than guarantees.
Despite the positive analyst sentiment and insider buying, the company faces headwinds from projected revenue contraction. The stock's performance relative to the S&P 500 has historically been slightly underperforming over a ten-year backtest period, suggesting investors should weigh the operational execution against sector-wide growth trends.
📈 Analysts see 9% upside potential with a $457 price target.
💰 Insiders show conviction via net buying of $1.4 million.
✅ Company beat EPS estimates by nearly 20% recently.
🔮 Simulations project a base case price near $615 by 2030.
📈 Elevance Health (ELV) trades at $419.17 with a consensus analyst price target of $457.00, indicating a 9% upside potential according to CleaRank Financial AI.
💰 Insiders have demonstrated conviction by purchasing $5.1 million in stock while selling only $3.7 million, signaling a net buy signal.
📉 Revenue estimates for the current and next quarters show a projected year-over-year decline of approximately 2.00%, lagging sector growth.
✅ The company recently exceeded EPS estimates by 19.97% in the quarter ending June 2026, demonstrating strong operational execution.
📊 Technical analysis shows the stock price is trading above its 50-day average of $397.60 with an RSI of 62 in neutral territory.
🔮 Long-term Monte Carlo simulations project a base case price near $615 by 2030, representing a 1.5x return from current levels over four years.
📉 A ten-year backtest indicates that an investment in ELV would have grown to approximately $34,119 compared to $35,344 for the S&P 500 benchmark.
Bullish Signals
Insiders bought $5.1M vs $3.7M sales, signaling conviction.
Exceeded EPS estimates by 19.97% in Q2 2026.
Analysts maintain Buy ratings with median target of $457.
Stock trades above 50-day average at $397.60.
Risk Factors
Revenue estimates project a year-over-year decline of approximately 2.00%.
Performance lags S&P 500 benchmark with $10k investment worth $34,119 vs $35,344.
Bullish Signals
Insiders purchased $5.1 million worth of stock against $3.7 million in sales, signaling a net buy signal and potential institutional conviction.
The company recently exceeded EPS estimates by 19.97% in the quarter to June 2026, indicating strong operational execution.
A majority of analysts maintain Buy or Overweight ratings with a median price target of $457.00, reflecting general Wall Street optimism.
Technical indicators show the stock trading above its 50-day average at $397.60 with an RSI of 62 in neutral territory.
Risk Factors
Current and next quarter revenue estimates project a year-over-year decline of approximately 2.00%, lagging behind the sector's positive growth.
Historical monthly performance trends show that a $10,000 investment in ELV would be worth about $34,119 today compared to $35,344 for the S&P 500 benchmark.
At the Wells Fargo 21st Annual Healthcare Conference, Elevance Health (ELV) CFO Marc Kaye reported that third-quarter adjusted earnings are tracking ahead of prior outlooks. The company reaffirmed its full-year 2026 adjusted earnings guidance of at least $27.00 per share and noted that 2026 is expected to be the trough year for Medicaid margins, with improvements anticipated in 2027 as rates align better with costs.
Management projects at least 12% adjusted EPS growth in 2027 relative to the 2026 baseline, driven by broad-based progress across multiple business segments rather than reliance on a single line. Elevance highlighted favorable cost trends in both Medicare Advantage and Medicaid markets, alongside stronger momentum within Carelon, its health services unit, signaling a diversified recovery strategy.
The market reacted positively to these updates, with ELV shares surging nearly 6% compared to UnitedHealth Group's decline. Investors view Elevance as demonstrating cleaner execution and upside surprise relative to peers, distinguishing it from competitors where guidance reaffirmations are seen merely as floors rather than catalysts for stock appreciation.
📈 Elevance Health Q3 adjusted earnings beat prior outlook.
💰 Reaffirmed 2026 EPS guidance of at least $27.00.
🚀 Forecasts at least 12% adjusted EPS growth in 2027.
📊 Improving cost trends across Medicare Advantage and Medicaid.
🏆 Stock surged nearly 6% on cleaner execution than peers.
📈 Elevance Health reported third-quarter adjusted earnings tracking ahead of its prior outlook following the Wells Fargo Healthcare Conference.
💰 The company reaffirmed full-year 2026 adjusted EPS guidance of at least $27.00 per share with a projected trough in Medicaid margins for that year.
🚀 Management forecasts at least 12% adjusted EPS growth in 2027 from the 2026 baseline supported by multiple business segments.
📊 Elevance highlighted improving cost trends across Medicare Advantage and Medicaid markets alongside stronger momentum in its Carelon health services unit.
🏆 The stock surged nearly 6% as investors distinguished Elevance's cleaner execution record from peers like UnitedHealth Group.
🔍 Analysts view the company's broad-based progress across segments as carrying more weight than single-line improvements seen elsewhere.
Bullish Signals
Q3 earnings beat prior outlook.
Reaffirmed FY2026 EPS guidance of $27.
Projects 12% adjusted EPS growth in 2027.
Shows favorable cost trends across markets.
Stock surged 6% on strong execution.
Bullish Signals
Third-quarter adjusted earnings are tracking ahead of the company's prior outlook, signaling strong operational performance.
The company reaffirmed full-year 2026 adjusted EPS guidance of at least $27.00 per share with a clear trajectory for improvement in Medicaid margins starting in 2027.
Management projects at least 12% adjusted EPS growth in 2027 from the 2026 baseline, supported by broad-based progress across multiple business segments.
Elevance demonstrated favorable cost trends in both Medicare Advantage and Medicaid markets while highlighting stronger momentum within its Carelon health services unit.
The stock surged nearly 6% immediately after the conference, reflecting investor confidence in the company's superior execution compared to peers.
Elevance Health stock declined by more than 2 percent intraday on September 9, 2026, as managed care insurers retreated amid sector-wide concerns over elevated medical expenses. The selling pressure was driven by a broader risk-off session where investors rotated out of health insurers following warnings from peers like CVS Health regarding rising costs, causing Elevance shares to fall alongside competitors such as UnitedHealth and Humana.
Despite the short-term price weakness, Elevance Health reported solid fundamental results in its second quarter of 2026, achieving double-digit growth in both revenue and earnings per year-over-year. These strong financials from its commercial and government businesses suggest the current share-price decline is primarily sentiment-driven rather than indicative of company-specific deterioration, though investors remain cautious about how rising medical costs at peers might eventually impact Elevance's own claims experience.
The company's full-year 2026 guidance, issued alongside Q2 results, assumed relatively stable utilization trends without baking in a significant jump in medical-loss ratios. This creates a potential risk if claims inflation accelerates more broadly across the industry, which could force Elevance Health to revisit its guidance and negatively affect future revenue growth and operating margins.
📉 ELV stock fell >2% intraday on Sept 9, 2026 due to sector rotation.
💰 Q2 2026 revenue and EPS grew double-digits versus prior year.
📈 Strong fundamentals frame weakness as sentiment-driven, not fundamental deterioration.
📉 Elevance Health stock fell by more than 2 percent intraday on September 9, 2026, as investors rotated out of the managed care sector amid rising medical cost concerns.
🏥 The decline occurred alongside peers including UnitedHealth, Centene, and Humana during a broader risk-off session driven by inflation worries and rising bond yields.
💰 Elevance Health reported double-digit growth in revenue and earnings per share for the second quarter of 2026 compared to the prior year.
📈 Strong Q2 fundamentals from commercial and government businesses frame the current stock weakness as sentiment-driven rather than a fundamental deterioration.
⚠️ The company's full-year 2026 guidance assumed stable utilization trends, creating potential risk if claims inflation accelerates beyond current expectations.
🏢 Elevance Health remains one of the largest managed care players in the S&P 500 index with a market capitalization in the tens of billions.
📊 The stock trades comfortably above its 52-week low but has given back recent gains as sector sentiment turned more cautious following peer warnings.
Risk Factors
Stock fell >2% amid sector retreat over high medical costs.
Guidance assumes stable utilization; risks if claims inflation accelerates.
Shares weighed down by rising yields and inflation worries.
Bullish Signals
Elevance Health reported double-digit growth in revenue and earnings per share for the second quarter of 2026 compared to the prior year.
Strong financial results from its commercial and government businesses indicate ongoing expansion despite recent sector-wide selling pressure.
Risk Factors
Elevance Health stock fell by more than 2 percent intraday on September 9, 2026, as investors retreated from the managed care sector due to concerns over elevated medical expenses.
The company's full-year 2026 guidance assumed stable utilization trends, creating a risk that Elevance may need to revisit its outlook if claims inflation accelerates broadly across the industry.
Rising bond yields and inflation worries contributed to a broader risk-off session that weighed heavily on Elevance Health shares alongside other health insurers.
Elevance Health Inc. (ELV) is a major health benefits organization serving approximately 118 million people across medical, pharmaceutical, behavioral health, and digital care solutions. Founded in 1944 and formerly known as Anthem, the company adopted its current name in June 2022. Based in Indianapolis, Indiana, ELV operates with a beta of 0.696, indicating below-market price volatility that appeals to investors seeking stability.
The company pays an annual dividend of $6.86 per share ($1.72 quarterly), resulting in a current yield of 1.68% at a stock price of $407.50. The next ex-dividend date is scheduled for September 10, 2026. ELV has demonstrated a strong track record with 13 consecutive years of dividend increases and a compound annual growth rate (CAGR) of 14.7% from 2011 to 2025.
Financially, Elevance Health maintains a conservative payout ratio of 30.4%, meaning it distributes only about one-third of its earnings as dividends. This low payout ratio provides substantial room to sustain or grow the dividend even if earnings face pressure. However, the current yield remains relatively low compared to high-yield alternatives, positioning ELV primarily for growth-and-income investors rather than those seeking immediate high income.
📈 ELV pays $1.72 quarterly dividend with 1.68% yield at $407.50 share price.
📅 Next ex-dividend date for ELV is September 10, 2026.
📊 ELV achieved 13 consecutive years of dividend growth with 14.7% CAGR.
🛡️ ELV maintains conservative 30.4% payout ratio ensuring dividend safety.
🏥 ELV serves 118 million individuals across medical and digital care solutions.
📈 Elevance Health Inc. (ELV) pays a $6.86 annual dividend ($1.72 quarterly) with a current yield of 1.68% at a share price of $407.50.
📅 The next ex-dividend date for ELV is set for September 10, 2026.
📊 ELV has achieved 13 consecutive years of dividend growth with a CAGR of 14.7% from 2011 to 2025.
🛡️ The company maintains a conservative payout ratio of 30.4%, distributing less than 40% of earnings to support dividend safety.
🏥 ELV serves approximately 118 million individuals across medical, pharmaceutical, behavioral health, and digital care solutions.
📉 The stock has a beta of 0.696, indicating below-market price volatility suitable for risk-averse investors.
🔄 Elevance Health Inc. rebranded from Anthem, Inc. to its current name in June 2022 while retaining its Indianapolis headquarters.
Bullish Signals
Serves 118M people, ensuring stable demand.
Conservative 30.4% payout ratio cushions dividend.
Strong capital return commitment to shareholders.
Risk Factors
Dividend yield of 1.68% limits income appeal vs high-yield alternatives.
Bullish Signals
Elevance Health Inc. has increased its dividend for 13 consecutive years, demonstrating a strong commitment to returning capital to shareholders.
The company maintains a conservative payout ratio of 30.4%, providing ample financial cushion to sustain or grow the dividend even if earnings decline.
ELV serves a massive scale of approximately 118 million people, creating broad and stable demand for its health benefits services.
Risk Factors
The current dividend yield of 1.68% is relatively low compared to high-yield alternatives, potentially limiting immediate income appeal for some investors.
Elevance Health Inc. (ELV) is a major health benefits organization serving approximately 118 million people across medical, pharmaceutical, behavioral health, and digital care solutions. Founded in 1944 and formerly known as Anthem, the company adopted its current name in June 2022. Based in Indianapolis, Indiana, ELV operates with a beta of 0.696, indicating below-market price volatility that appeals to investors seeking stability.
The company pays an annual dividend of $6.86 per share ($1.72 quarterly), resulting in a current yield of 1.68% at a stock price of $407.50. The next ex-dividend date is scheduled for September 10, 2026. Over the past 15 years, ELV has demonstrated a compound annual dividend growth rate (CAGR) of 14.7%, with 13 consecutive years of increases, highlighting a strong history of rewarding shareholders despite a modest starting yield.
Financially, Elevance Health maintains a conservative payout ratio of 30.4% of earnings, which provides substantial room to sustain and grow the dividend even if earnings face pressure. While the current yield is below 2%, it sits slightly above the company's 5-year average of 1.42%. The primary risk identified for dividend safety involves regulatory and reimbursement changes in the healthcare industry that could compress margins without warning.
ELV is positioned as a growth-and-income investment rather than a high-yield alternative, offering a rising dividend stream from a large-scale business with broad demand. The low payout ratio ensures the dividend is well-covered by earnings, leaving no meaningful pressure on the current payout level while providing portfolio diversification alongside income generation.
📈 ELV pays $6.86 annual dividend with 14.7% CAGR growth since 2011.
📅 Next ex-dividend date is September 10, 2026 for medical care solutions.
📉 Beta of 0.696 offers below-market volatility suitable for dividend investors.
📊 Conservative 30.4% payout ratio provides substantial room to sustain dividends.
⚠️ Regulatory changes in healthcare plans could compress margins and test safety.
📈 Elevance Health Inc. (ELV) pays a $6.86 annual dividend ($1.72 quarterly), yielding 1.68% at a share price of $407.50.
📅 The next ex-dividend date for ELV is set for September 10, 2026, with payments covering medical, pharmaceutical, and digital care solutions for 118 million people.
📉 ELV has a beta of 0.696, indicating below-market price swings that suit investors seeking dividend growth without sharp portfolio volatility.
📊 The company maintains a conservative payout ratio of 30.4% of earnings, providing substantial room to sustain the dividend even if earnings face pressure.
📈 ELV has achieved a compound annual dividend growth rate (CAGR) of 14.7% from 2011 to 2025, with 13 consecutive years of increases.
🛡️ The current yield of 1.68% sits above the company's 5-year average of 1.42%, offering slightly more income than recent historical norms.
⚠️ Dividend safety faces credible tests from regulatory and reimbursement changes in the healthcare plans industry that could compress margins.
Bullish Signals
Elevance Health Inc. has increased its dividend for 13 consecutive years, demonstrating a strong commitment to shareholder returns.
The company maintains a conservative payout ratio of 30.4% of earnings, ensuring the dividend is well-covered and sustainable even if earnings face pressure.
ELV serves approximately 118 million people across medical, pharmaceutical, behavioral health, and digital care solutions, creating broad demand for its services.
The current dividend yield of 1.68% is slightly higher than the company's 5-year average of 1.42%, offering a modestly better entry yield than historical norms.
With a beta of 0.696, ELV offers below-market price volatility, making it suitable for investors who want dividend growth without sharp portfolio swings.
Risk Factors
Dividend safety faces its most credible test from regulatory and reimbursement changes in the healthcare plans industry, which can compress margins without warning.
The current yield of 1.68% is below 2%, meaning it will not satisfy investors who need meaningful current income from day one compared to high-yield alternatives.
Elevance Health (ELV) has gained 37.5% over the past 12 months, yet valuation metrics suggest the stock remains undervalued relative to its fundamentals and peers. The company currently trades at a P/E ratio of 18.1x, which is significantly lower than the wider healthcare industry average of 25.3x and a peer group average of 27.8x.
Analysts estimate a fair P/E multiple for Elevance Health to be approximately 34.8x, indicating a substantial gap between current market pricing and implied value. This discount persists despite recent strategic initiatives, including the appointment of Dr. Patrick Fox to lead Carelon Behavioral Services and increased investment in AI-driven efficiencies.
The core investment thesis hinges on whether Elevance Health can successfully manage rising costs associated with government-backed plans and value-based care models. If the company can maintain margin stability through its technology investments and operational improvements, the current valuation may appear conservative. Conversely, if these external cost pressures outweigh internal efficiencies, the multiple could be justified as fair rather than cheap.
📈 ELV returned 37.5% in 12 months but remains undervalued.
📊 ELV trades at 18.1x P/E vs 25.3x industry average.
🎯 Analysts estimate fair P/E of 34.8x for ELV.
👤 Dr. Patrick Fox leads Carelon Behavioral Services for growth.
⚠️ Government plan costs risk compressing ELV margins.
📈 Elevance Health (ELV) has returned 37.5% over the last 12 months, yet valuation checks still classify it as undervalued.
📊 The stock trades at a P/E of 18.1x, well below the healthcare industry average of 25.3x and peer group average of 27.8x.
🎯 Analysts estimate a fair P/E multiple of 34.8x for Elevance Health, suggesting a significant undervaluation gap.
👤 Dr. Patrick Fox has been appointed to lead Carelon Behavioral Services to support profitable growth expectations.
🤖 The company is expanding the use of AI in its business to boost efficiency and reduce operational costs.
⚠️ Elevated costs in government-backed plans pose a risk that could compress margins despite operational improvements.
🏥 Greater reliance on value-based care models presents a potential headwind for Elevance Health's profitability.
💰 The company operates with an excellent balance sheet and currently pays a dividend to shareholders.
Bullish Signals
P/E of 18.1x is lower than industry average of 25.3x.
Fair P/E multiple of 34.8x indicates sizeable undervaluation.
Dr. Patrick Fox appointment supports profitable growth expectations.
Tech investments boost efficiency and reduce operational costs.
Excellent balance sheet with dividend provides financial stability.
Bullish Signals
Elevance Health trades at a P/E of 18.1x, which is materially lower than the healthcare industry average of 25.3x and peer group average of 27.8x.
Analysts estimate a fair P/E multiple of 34.8x for Elevance Health, indicating the current market price implies a sizeable undervaluation gap.
The appointment of Dr. Patrick Fox to lead Carelon Behavioral Services is expected to support expectations for profitable growth.
Technology investments in analytics, digitization, and AI are boosting efficiency and reducing costs across Elevance Health's operations.
Elevance Health operates with an excellent balance sheet and pays a dividend, providing financial stability.
Risk Factors
Elevated costs in government-backed plans could compress margins despite the company's operational improvements and diversification strategies.
Greater reliance on value-based care models presents a risk that may hinder Elevance Health's ability to maintain high profit margins.
Elevance Health (ELV) has gained 37.5% over the past 12 months, yet analysts at Simply Wall St argue the stock remains undervalued based on fundamental metrics. The company currently trades at a Price-to-Earnings ratio of 18.1x, which is significantly lower than the wider healthcare industry average of 25.3x and its peer group average of 27.8x.
Despite recent share price strength, valuation models suggest a fair P/E multiple closer to 34.8x, implying a substantial gap between current market pricing and estimated intrinsic value. The article highlights that while the stock has rallied, it still screens as inexpensive relative to both historical benchmarks and comparable healthcare peers.
Key drivers for future performance include the appointment of Dr. Patrick Fox to lead Carelon Behavioral Services and increased adoption of AI technologies aimed at boosting operational efficiency. However, risks remain regarding elevated costs in government-backed plans and the potential margin compression from a greater reliance on value-based care models.
📉 ELV returned 37.5% in 12 months, raising valuation questions.
📊 ELV trades at 18.1x P/E vs 25.3x industry average.
🎯 Analysts estimate fair ELV P/E multiple of 34.8x.
👤 Dr. Patrick Fox leads Carelon Behavioral Services for growth.
⚠️ Government plan costs risk compressing ELV margins.
📉 Elevance Health (ELV) has returned 37.5% over the last 12 months, raising questions about whether recent gains have fully priced in its fundamentals.
📊 The stock trades at a P/E ratio of 18.1x, which is materially lower than the healthcare industry average of 25.3x and peer group average of 27.8x.
🎯 Analysts estimate a fair P/E multiple for Elevance Health of 34.8x, suggesting the current market price implies a significant undervaluation gap.
👤 Dr. Patrick Fox has been appointed to lead Carelon Behavioral Services to support expectations for profitable growth in that segment.
🤖 The company is expanding its use of AI and technology investments to boost efficiency and reduce operational costs.
⚠️ Elevated costs associated with government-backed plans pose a risk of compressing margins despite ongoing operational improvements.
🏥 Greater reliance on value-based care models could further impact profitability if execution challenges arise during scaling efforts.
Risk Factors
Gov plan costs may compress margins.
Value-care scaling risks margin pressure.
Bullish Signals
Elevance Health trades at a P/E ratio of 18.1x, which is substantially below the healthcare industry average of 25.3x and peer group average of 27.8x.
Analysts estimate a fair P/E multiple of 34.8x for Elevance Health, indicating the current market price may be significantly undervalued relative to fundamentals.
The appointment of Dr. Patrick Fox to lead Carelon Behavioral Services is expected to support profitable growth in that specific business segment.
Risk Factors
Elevated costs in government-backed plans could compress margins despite the company's operational improvements and diversification strategies.
Greater reliance on value-based care models presents a risk of margin pressure if execution challenges arise during scaling efforts.
Elevance Health, Inc. (ELV) is a major US managed healthcare company serving tens of millions of members through employer-sponsored, individual, Medicaid, and Medicare plans. It operates as the licensed Blue Cross Blue Shield provider in 14 states, making it the largest single BCBS operator in the country, which provides strong market positioning among employers and government programs.
The company has strategically expanded beyond traditional commercial insurance by acquiring Amerigroup in 2012 to strengthen Medicaid capabilities and purchasing MMM in Puerto Rico to broaden its Medicare Advantage reach. These acquisitions expose Elevance to long-term demand from aging populations while requiring careful management of regulatory environments, reimbursement rates, and medical cost trends.
Elevance is shifting toward an integrated healthcare model through its Carelon segment, which offers pharmacy services, behavioral health, payment integrity, and care management capabilities. This strategy aims to capture more value along the healthcare chain and improve member outcomes, positioning ELV as a significant insurer with scale and growing exposure to healthcare services beyond traditional underwriting.
Recent market data indicates strong analyst sentiment with 69% of analysts rating Elevance Health as a Buy, while insider activity shows net buying of approximately $541.7K over the last 90 days. Technical signals are mixed regarding long-term trends but supportive in the near term, with MACD momentum indicating positive short-term potential.
🏥 Serves tens of millions via diverse US health plans.
🛡️ Largest single Blue Cross Blue Shield operator in 14 states.
🔄 Carelon segment drives integrated healthcare model expansion.
💰 69% of analysts rate stock as a Buy.
👔 Insiders net bought $541.7K over last 90 days.
🏥 Elevance Health serves tens of millions of members via employer-sponsored, individual, Medicaid, and Medicare-related plans across the US.
🛡️ The company is the licensed Blue Cross Blue Shield operator in 14 states, making it the largest single BCBS provider in the country.
📈 Acquisitions like Amerigroup (2012) and MMM (Puerto Rico) expanded Medicaid and Medicare Advantage capabilities respectively.
🔄 The Carelon segment drives a shift toward an integrated healthcare model including pharmacy and behavioral health services.
💰 Analyst sentiment is strongly positive with 69% of analysts rating Elevance Health as a Buy.
👔 Insiders were net buyers of approximately $541.7K in stock over the last 90 days.
📊 Technical indicators show mixed long-term trends but supportive near-term MACD momentum and neutral RSI.
Bullish Signals
69% of analysts rate Elevance Health as a Buy.
$541.7K net insider purchases over last 90 days.
Carelon segment diversifies revenue beyond traditional insurance underwriting.
Largest BCBS operator in 14 states provides stable moat.
Bullish Signals
Strong analyst consensus with 69% of analysts rating Elevance Health as a Buy indicates robust market confidence in the company's fundamentals.
Significant insider buying activity, with net purchases of approximately $541.7K over the last 90 days, suggests management views the stock favorably.
Strategic expansion into pharmacy benefit management and care delivery via the Carelon segment diversifies revenue streams beyond traditional insurance underwriting.
Dominant market position as the largest single Blue Cross Blue Shield operator in 14 states provides a stable competitive moat in local insurance markets.
AIA Group Ltd reduced its stake in Elevance Health, Inc. (NYSE:ELV) by 30.3% in the first quarter, selling 21,370 shares and retaining a position worth approximately $14.4 million. While AIA exited significantly, other institutional investors like Kemnay Advisory Services, J.Safra Asset Management, ORG Partners LLC, Dorato Capital Management, and Loring Wolcott & Coolidge increased their holdings during the fourth quarter, with ORG Partners notably lifting its position by over 120%.
Elevance Health reported a market capitalization of $80.82 billion with key financial metrics including a price-to-earnings ratio of 16.56 and a debt-to-equity ratio of 0.68. The stock trades at $372.68, positioned between its 50-day moving average of $399.55 and 200-day average of $355.35, with an annualized dividend yield of 1.8% set to be paid on September 25th.
Analyst sentiment remains cautiously positive with a consensus rating of 'Moderate Buy' and an average price target of $440.90. Major institutions like Bank of America and Morgan Stanley raised their price targets recently, while Goldman Sachs maintained a neutral stance at $395. The company continues to focus on integrated health care delivery under CEO Gail Boudreaux.
📉 AIA Group sold shares, reducing stake by 30.3% to $14.4M.
📈 ORG Partners increased holding by 120.4% to own 108 shares.
💰 Market cap is $80.82B with P/E of 16.56 and debt-to-equity of 0.68.
📅 Quarterly dividend of $1.72 payable Sept 25 to record holders Sept 10.
🎯 Bank of America raised target to $460; Morgan Stanley set at $404.
📉 AIA Group Ltd lowered its Elevance Health position by 30.3% in Q1, selling 21,370 shares while retaining a $14.4 million stake.
📈 ORG Partners LLC increased its holding by 120.4% in Q4, acquiring an additional 59 shares to own 108 total shares.
💰 Elevance Health maintains a market cap of $80.82 billion with a P/E ratio of 16.56 and a debt-to-equity ratio of 0.68.
📅 The company announced a quarterly dividend of $1.72 per share, payable on September 25th to shareholders of record on September 10th.
🎯 Bank of America raised its price target from $435 to $460 and reaffirmed a 'buy' rating in a recent report.
📊 Morgan Stanley increased its target price from $352 to $404, assigning an 'equal weight' rating to the stock.
👔 Director Robert L. Dixon, Jr. sold 151 shares for approximately $60,667 in a transaction on June 11th.
🏥 Elevance Health operates as a major U.S. health benefits provider offering medical plans for individuals, employers, and government programs.
📉 The stock currently trades at $372.68, sitting below its 50-day moving average of $399.55 but above its 200-day average of $355.35.
🔍 Institutional ownership stands at 89.24%, indicating strong interest from hedge funds and asset managers.
Bullish Signals
Analyst consensus is Moderate Buy with $440.90 price target.
Bank of America raised target to $460; Morgan Stanley to $404.
Healthy balance sheet: debt-to-equity 0.68 and current ratio 1.52.
Institutional investors like ORG Partners LLC increased stakes significantly.
Risk Factors
AIA Group reduced position by 30.3% in Q1.
Goldman Sachs neutral rating targets $395 vs $372.68 price.
Bullish Signals
Analyst consensus is 'Moderate Buy' with an average price target of $440.90, suggesting upside potential from current levels.
Bank of America boosted its price target to $460 and Morgan Stanley raised theirs to $404, reflecting confidence in the company's outlook.
The company maintains a healthy balance sheet with a debt-to-equity ratio of 0.68 and a current ratio of 1.52.
Institutional investors like ORG Partners LLC significantly increased their stakes, signaling continued institutional interest.
Risk Factors
AIA Group Ltd reduced its position by 30.3% in the first quarter, indicating some large-scale profit-taking or de-risking.
Goldman Sachs restated a 'neutral' rating with a price objective of $395, which is below the current trading price of $372.68 but implies limited upside.
Elevance Health (NYSE:ELV) raised its 2026 adjusted earnings outlook following second-quarter results that exceeded management expectations. CEO Gail Boudreaux stated the company now expects 2026 adjusted diluted EPS of at least $27, up from a previous baseline of $26. The company cited favorable benefit expense performance and disciplined cost management as key drivers, with confidence in returning to at least 12% adjusted EPS growth in 2027.
Management addressed ongoing challenges in the Medicaid segment, maintaining a full-year operating margin outlook of approximately negative 1.75%. While rate updates were stronger than anticipated, executives noted that cost drivers remain elevated in behavioral health and specialty pharmacy. The company confirmed it will exit the District of Columbia Medicaid market and plans to withdraw from additional markets over the next 12 to 18 months where sustainable performance is not viable.
Performance in Medicare Advantage was stronger than expected, contributing to quarterly outperformance as the company repositions its portfolio toward dual-eligible special needs plans and HMO products. Elevance remains on track for at least a 2% operating margin in this segment for 2026. In the individual ACA business, member retention is ahead of expectations, with the company projecting at least 1 million members by year-end.
Commercial health benefits performance aligned with expectations, highlighted by a record year in national accounts for 2026 and a robust pipeline for 2027. Carelon's growth strategy continues to focus on home-based care via CareBridge and behavioral health programs that have delivered average cost savings of 10%. The company reported second-quarter operating cash flow of $1.9 billion and raised its full-year outlook to at least $6 billion.
📈 EPS outlook raised to at least $27 for 2026.
💰 Projected 12% adjusted EPS growth expected in 2027.
🏥 Medicaid margin remains negative 1.75% with market exits planned.
📊 ACA member retention ahead of expectations reaching 1 million.
💵 Full-year operating cash flow outlook raised to at least $6B.
📈 Elevance Health raised its 2026 adjusted diluted EPS outlook to at least $27, citing favorable benefit expense performance and disciplined cost management.
💰 The company expects to return to at least 12% adjusted EPS growth in 2027 off the higher baseline of $26.
🏥 Medicaid operating margin outlook remains at approximately negative 1.75%, with exits planned for D.C. and other unsustainable markets over the next 12-18 months.
📊 Medicare Advantage results were stronger than expected, driving portfolio repositioning toward dual-eligible special needs plans and HMO products.
👥 Individual ACA member retention is modestly ahead of expectations, with a projected total of at least 1 million members by end of 2026.
💼 Commercial health benefits saw a record year in national accounts for 2026 with a nearly as large pipeline for 2027.
🚀 Carelon's CareBridge home-care model is being expanded into new markets to generate mid-teens medical savings for members.
💵 Second-quarter operating cash flow reached $1.9 billion, prompting a raised full-year outlook of at least $6 billion.
⚖️ Elevance received written confirmation from CMS that sanctions will not be imposed regarding a prior matter, closing the issue as of July 9.
🔧 The company plans to use a net below-the-line benefit of $0.80 per share for one-time investments in cost management and AI-enabled tools.
Bullish Signals
Raised 2026 EPS outlook to at least $27.
Expects 12% adjusted EPS growth in 2027.
Medicare Advantage results stronger than expected.
Projected total of at least 1 million members by end of 2026.
Commercial health benefits saw a record year in national accounts for 2026.
Carelon's behavioral health programs delivered average cost savings of 10%.
Elevance received written confirmation from CMS that sanctions will not be imposed.
Risk Factors
Medicaid operating margin outlook remains at approximately negative 1.75%.
Company plans to exit DC Medicaid and other markets soon.
Days in claims payable increased to 45.4 days as of June.
Bullish Signals
Elevance Health raised its 2026 adjusted diluted EPS outlook to at least $27, driven by favorable benefit expense performance and disciplined cost management.
The company expects to return to at least 12% adjusted EPS growth in 2027 off the higher baseline of $26.
Medicare Advantage results were stronger than expected, contributing to quarterly outperformance as the portfolio repositions toward dual-eligible special needs plans and HMO products.
Individual ACA member retention is modestly ahead of expectations, with a projected total of at least 1 million members by end of 2026.
Commercial health benefits saw a record year in national accounts for 2026 with a nearly as large pipeline for 2027.
Carelon's behavioral health programs have delivered average cost savings of 10% through stronger member engagement and fewer adverse events.
Second-quarter operating cash flow reached $1.9 billion, prompting a raised full-year outlook of at least $6 billion.
Elevance received written confirmation from CMS that sanctions will not be imposed regarding a prior matter, closing the issue as of July 9.
Risk Factors
Medicaid operating margin outlook remains at approximately negative 1.75%, with cost drivers remaining elevated in behavioral health and specialty pharmacy.
The company plans to exit the District of Columbia Medicaid market and intends to withdraw from additional markets over the next 12-18 months where sustainable performance is not viable.
Days in claims payable increased to 45.4 days as of June 30, up 2.9 days from a year earlier, though management maintains confidence in reserving levels.
ARGA Investment Management LP reduced its stake in Elevance Health, Inc. (NYSE:ELV) by 26.2% in the first quarter, selling 72,692 shares to hold a remaining position of 205,063 shares valued at approximately $60 million. This reduction brings the stock to its 11th largest position within the fund's portfolio, representing about 2.0% of total holdings.
Conversely, several major institutional investors significantly increased their exposure to Elevance Health during the fourth quarter. Norges Bank initiated a new position worth roughly $1.06 billion, while Wellington Management Group grew its stake by 25.2% to a value of $2.91 billion. Other notable increases include Price T Rowe Associates (up 27.5%), Invesco Ltd. (up 50.3%), and Bank of New York Mellon Corp (up 79.3%).
Analyst sentiment remains mixed but generally positive, with a consensus rating of 'Moderate Buy' and an average price target of $425.95. Major banks like Barclays and JPMorgan Chase raised their price targets to $480 and $476 respectively, citing overweight ratings, while Wall Street Zen upgraded the stock to a buy rating. The company maintains a market cap of $90.46 billion with a dividend yield of 1.7%.
📉 ARGA Investment reduced holdings by 26.2% to retain a $60 million position.
📈 Wellington Management increased stake by 25.2% to own $2.91 billion in shares.
💰 Company pays quarterly dividend of $1.72 per share for 1.7% annualized yield.
🏦 Institutional ownership stands at 89.24% with a market cap of $90.46 billion.
📊 Analysts maintain overweight ratings with price targets ranging from $391 to $480.
📉 ARGA Investment Management LP reduced its Elevance Health holdings by 26.2%, selling 72,692 shares to retain a $60 million position.
📈 Norges Bank established a new $1.06 billion position in Elevance Health during the fourth quarter.
📈 Wellington Management Group increased its stake by 25.2% to own 8.29 million shares valued at $2.91 billion.
📈 Price T Rowe Associates Inc. MD grew its holdings by 27.5%, now owning 7.45 million shares worth $2.61 billion.
📈 Invesco Ltd. significantly expanded its position by 50.3% to hold 3.9 million shares valued at $1.37 billion.
📈 Bank of New York Mellon Corp raised its stake by 79.3%, purchasing an additional 1.07 million shares.
🏦 Institutional ownership of Elevance Health stands at 89.24% as of the latest filings.
💰 The company recently paid a quarterly dividend of $1.72 per share, resulting in a 1.7% annualized yield.
📊 Barclays raised its price target to $480 and maintained an 'overweight' rating on the stock.
📈 JPMorgan Chase increased its price objective to $476 with an 'overweight' recommendation.
🚀 Wall Street Zen upgraded Elevance Health from a 'hold' to a 'buy' rating in late June.
📉 Jefferies Financial Group lowered its price target to $391 but maintained a 'buy' rating.
👔 CEO Gail Boudreaux leads the company's strategic focus on integrated health care and benefit delivery.
🏢 Elevance Health operates as a large U.S.-based health benefits provider headquartered in Indianapolis.
📉 The stock trades at a PE ratio of 17.72 with a market capitalization of $90.46 billion.
📉 Director Robert L. Dixon, Jr. sold 151 shares for approximately $60,667 in a recent transaction.
Bullish Signals
Major investors increased stakes significantly in Q4.
Barclays raised target to $480 with overweight rating.
JPMorgan Chase set $476 target and overweight rating.
Wall Street Zen upgraded stock from hold to buy.
Healthy 1.7% dividend yield with 29.26% payout ratio.
Invesco doubled holdings by 50.3%.
Risk Factors
ARGA Investment reduced position by 26.2% in Q1.
Jefferies lowered price target to $391.
Stock volatility: 52-week low $273.71, high $427.64.
Bullish Signals
Major institutional investors including Norges Bank, Wellington Management Group, and Price T Rowe Associates significantly increased their stakes in the fourth quarter.
Barclays raised its price target to $480 and assigned an 'overweight' rating, indicating strong confidence in future performance.
JPMorgan Chase increased its price target to $476 with an 'overweight' rating, reinforcing bullish analyst sentiment.
Wall Street Zen upgraded the stock from a 'hold' to a 'buy' rating, signaling improved investment outlook.
The company maintains a healthy dividend yield of 1.7% with a payout ratio of 29.26%, providing income to shareholders.
Invesco Ltd. more than doubled its holdings by 50.3%, demonstrating strong institutional interest in the stock.
Risk Factors
ARGA Investment Management LP reduced its position by 26.2% in the first quarter, indicating a decrease in confidence from this specific fund.
Jefferies Financial Group lowered its price target to $391, suggesting some analysts see limited upside at current levels.
The stock has experienced volatility with a 52-week low of $273.71 compared to a high of $427.64.
Elevance Health (NYSE:ELV) has filed a lawsuit against the Centers for Medicare & Medicaid Services (CMS) regarding the recalculation of Medicare Advantage star ratings. The company alleges that CMS applied different processes to Elevance compared to competitor Clover Health, resulting in a substantial loss of bonus payments.
The dispute centers on regulatory consistency and could significantly influence how quality scores and related payments are handled for Medicare insurers. Specifically, the lawsuit claims the revised star rating process cost Elevance approximately US$115 million in bonus payments after the agency treated the company differently than Clover Health.
This legal challenge highlights the risks associated with government-backed business models, exposing Elevance to regulatory decisions that can pressure earnings even when internal operations are sound. The outcome may affect not only Elevance but also other insurers like UnitedHealth and Humana regarding the stability of star ratings and revenue streams.
Investors should monitor the legal timeline, interim court decisions, and whether CMS signals broader changes to Medicare Advantage rules. Management's framing of the potential financial impact of the disputed US$115 million in upcoming filings will be a key indicator for future cash flow certainty and pricing flexibility.
⚖️ Elevance sues CMS over inconsistent Medicare Advantage star rating processes.
💰 Company claims disputed process caused $115 million in lost bonus payments.
📉 Regulatory uncertainty threatens earnings and future Medicare Advantage margins.
🏥 Dispute involves competitors UnitedHealth, CVS Aetna, and Humana on ratings.
📈 Stock trades at $417.89 with 18.0% year-to-date return as of publication.
⚖️ Elevance Health has filed a lawsuit against CMS alleging inconsistent application of Medicare Advantage star rating processes compared to Clover Health.
💰 The company claims the disputed regulatory process resulted in a loss of approximately US$115 million in bonus payments.
📉 The legal challenge exposes Elevance to regulatory uncertainty that could pressure earnings and influence future Medicare Advantage margins.
🏥 The dispute involves key competitors including UnitedHealth, CVS Health's Aetna unit, and Humana regarding rating stability.
🔍 A favorable ruling could restore the disputed bonuses and enforce more transparent CMS methodologies across the industry.
📈 Elevance Health stock is currently trading at $417.89 with an 18.0% return year to date as of the article's publication.
⚠️ Investors face risks if the court sides with CMS or if the legal process drags on without recovery of lost payments.
📊 The case underscores the sensitivity of Elevance's Medicare Advantage earnings to how CMS interprets and applies its own rules.
🔮 Future updates will depend on whether this dispute is an isolated issue or part of a wider pattern of reimbursement friction.
Bullish Signals
Restore ~US$115M in disputed bonus payments.
Support long-term planning with transparent CMS methodologies.
Potential lost bonus payments and unpredictable future rule changes.
Government exposure pressures earnings despite effective internal cost control.
Bullish Signals
A favorable ruling requiring CMS to recalculate ratings using the same approach as Clover Health could restore approximately US$115 million in disputed bonus payments.
The case may push for more transparent and uniform CMS methodologies, supporting Elevance's long-term planning and data-focused efforts like Health OS.
Risk Factors
The lawsuit highlights that Elevance Health's Medicare Advantage earnings are sensitive to how CMS interprets rules, adding legal and regulatory uncertainty to future cash flows.
If the court sides with CMS or the process drags on, investors could face a period where lost bonus payments are not recovered and future rule changes remain unpredictable.
The dispute underlines a narrative risk that government-backed business leaves Elevance exposed to regulatory decisions that can pressure earnings even when internal cost-control tools are effective.
Assenagon Asset Management S.A. significantly reduced its stake in Elevance Health, Inc. (NYSE:ELV) by 78.3% during the first quarter, selling 414,729 shares to hold a remaining position of 114,779 shares valued at $33.6 million. While Assenagon exited substantially, other institutional investors like Kemnay Advisory Services Inc., J.Safra Asset Management Corp, and ORG Partners LLC established or increased new positions in the fourth quarter, with hedge funds collectively owning 89.24% of the company's stock.
Elevance Health reported strong quarterly financial results on April 22nd, posting $12.58 earnings per share which beat analyst consensus estimates of $10.74 by $1.84. The company generated revenue of $49.49 billion, surpassing the estimated $48.21 billion, with a net margin of 2.62% and a return on equity of 15.58%. Revenue grew by 1.5% year-over-year to $49.49 billion, demonstrating consistent top-line performance despite a modest increase compared to the prior year.
The company recently declared a quarterly dividend paid on June 25th to stockholders of record as of June 10th, distributing $1.72 per share which annualizes to $6.88 and yields 1.7%. Director Robert L. Dixon, Jr. sold 151 shares for approximately $60,667 in a transaction on June 11th, reducing his personal ownership by 1.39% while retaining over 10,000 shares valued at roughly $4.3 million. The stock currently trades with a market cap of $85.75 billion and a P/E ratio of 16.80.
📉 Assenagon cut Elevance Health holdings by 78.3% to $33.6M.
💰 Q1 EPS hit $12.58, beating estimates by $1.84.
📊 Revenue reached $49.49B, up 1.5% year-over-year.
💵 Quarterly dividend of $1.72/share with 1.7% yield.
👔 Director Robert Dixon sold shares, retaining over 10,000.
📉 Assenagon Asset Management S.A. cut its Elevance Health holdings by 78.3% in Q1, selling 414,729 shares to retain a $33.6 million position.
📈 Multiple other institutions including Kemnay Advisory Services Inc., J.Safra Asset Management Corp, and ORG Partners LLC initiated or increased positions in the fourth quarter.
💰 Elevance Health reported Q1 EPS of $12.58, beating analyst estimates of $10.74 by $1.84.
📊 Revenue reached $49.49 billion for the quarter, exceeding expectations of $48.21 billion and growing 1.5% year-over-year.
💵 The company declared a quarterly dividend of $1.72 per share with an annualized yield of 1.7% paid on June 25th.
👔 Director Robert L. Dixon, Jr. sold 151 shares for $60,667 on June 11th, reducing his stake by 1.39% while retaining over 10,000 shares.
📉 The stock trades at a P/E ratio of 16.80 with a market capitalization of $85.75 billion.
🏥 CEO Gail Boudreaux leads the company's strategic focus on integrated health care and benefit delivery following its rebrand from Anthem in 2022.
Elevance Health (ELV) recently announced upgrades to its Health OS platform, which integrates with electronic health records and Epic's Payer Platform. These enhancements aim to simplify clinical reviews, prior authorizations, and care coordination for both providers and members, signaling continued investment in digital infrastructure.
The stock is currently trading at US$395.10, reflecting a 33.44% gain over the last 90 days but a 6.64% decline over three years. Analysts project annual revenue growth of 6.8% and an expansion in profit margins from 2.8% to 3.2% over the next three years, though the company faces headwinds from rising medical costs and shifting government policies.
Valuation analysis presents mixed signals: a narrative fair value model suggests the stock is modestly overvalued at US$395.10 versus a target of US$387.85. However, the current P/E ratio of 16.4x appears attractive compared to a historical average of 30.7x and an industry average of 23.1x, creating a debate over whether the market is correctly pricing policy risks or underestimating earnings power.
Investors must weigh the company's strong recent momentum against potential margin compression from elevated medical cost trends and regulatory changes in Medicare Advantage and ACA markets. The article concludes that while digital initiatives are positive, the valuation remains complex due to conflicting signals between narrative models and traditional earnings multiples.
🏥 Elevance Health launches new Health OS capabilities for Epic integration.
💰 Stock hit $395.10 with 33.44% return over last 90 days.
📈 Analysts forecast 6.8% revenue growth and margin rise to 3.2%.
⚖️ Narrative model targets $387.85, labeling stock modestly overvalued.
📊 Current P/E of 16.4x is below historical average of 30.7x.
🏥 Elevance Health launched new Health OS capabilities connecting directly with Epic's Payer Platform to streamline clinical reviews and prior authorizations.
💰 The stock price reached US$395.10, marking a 33.44% return over the last 90 days despite a 6.64% decline over the past three years.
📈 Analysts forecast annual revenue growth of 6.8% and an increase in profit margins from 2.8% to 3.2% over the next three years.
⚖️ A narrative fair value model estimates a target price of US$387.85, labeling the current stock as modestly overvalued.
📊 The current P/E ratio of 16.4x is significantly lower than the 30.7x historical average and 23.1x industry average, suggesting potential undervaluation.
⚠️ The company faces pressure from elevated medical cost trends that could cap future margin expansion.
🏛️ Shifting Medicare Advantage and ACA policies pose regulatory risks that could challenge the current earnings narrative.
🤖 The article highlights ELV as a key example of healthcare companies utilizing AI in care delivery and operations.
Bullish Signals
Expanding Health OS platform with new Epic integrations.
Delivered strong 33.44% return over last 90 days.
Projected steady revenue growth of 6.8% annually.
Profit margins improving from 2.8% to 3.2% in three years.
Current P/E ratio of 16.4x is below historical average.
Risk Factors
Elevated medical costs limit margin expansion and challenge forecasts.
Policy shifts introduce regulatory uncertainty capping margins and growth.
Stock overvalued at $395.10 vs. $387.85 target price.
Bullish Signals
Elevance Health is expanding its Health OS platform with new integrations to Epic, demonstrating strategic growth in digital health infrastructure.
The stock has delivered a strong 33.44% return over the last 90 days, indicating significant recent market momentum.
Analysts project steady revenue growth of 6.8% annually and an improvement in profit margins from 2.8% to 3.2% over the next three years.
The current P/E ratio of 16.4x is substantially lower than both the historical average of 30.7x and the industry average of 23.1x, suggesting potential value.
Risk Factors
Elevance Health faces real pressure from elevated medical cost trends that could limit margin expansion and challenge current forecasts.
Shifting Medicare Advantage and ACA policies introduce regulatory uncertainty that could cap margins and disrupt the company's growth narrative.
A narrative fair value model suggests the stock is modestly overvalued at US$395.10 compared to a target price of US$387.85.
Elevance Health, Inc. (NYSE: ELV) is a major U.S. healthcare company with a market capitalization of $84.37 billion, trading at $388.50. Analysts project an average target price of $415.81, implying approximately 7% upside potential from current levels. The stock has experienced volatility within its 52-week range of $274.66 to $424.43.
Financial metrics highlight a Forward P/E ratio of 13.28 and robust free cash flow exceeding $4.29 billion, supporting operations and shareholder returns. The company offers a dividend yield of 1.77% with a conservative payout ratio of 29.03%. Recent performance shows modest revenue growth of 2.60%, an EPS of $23.58, and a Return on Equity of 12.09%.
Analyst sentiment is overwhelmingly positive, with 14 buy ratings and no sell ratings. Technical indicators suggest potential bullish momentum, as the Relative Strength Index (RSI) sits at 32.16 near oversold territory and the MACD line remains above the signal line. The company operates through diversified segments including Health Benefits, CarelonRx, and Carelon Services under brands like Anthem Blue Cross and Blue Shield.
📈 Stock trades at $388.50 with 7.03% upside potential.
💰 Generates over $4.29B free cash flow and EPS of $23.58.
👍 Strong bullish sentiment with 14 buy ratings and zero sells.
📉 RSI at 32.16 indicates oversold conditions with positive momentum.
🏥 Operates via Health Benefits, CarelonRx, and Carelon Services segments.
📈 Elevance Health trades at $388.50 with an average analyst target price of $415.81, suggesting a 7.03% upside potential.
💰 The company reports a Forward P/E ratio of 13.28 and generates over $4.29 billion in free cash flow.
📊 Financial performance includes an EPS of $23.58, a Return on Equity of 12.09%, and modest revenue growth of 2.60%.
💵 Shareholders receive a dividend yield of 1.77% supported by a conservative 29.03% payout ratio.
👍 Analyst sentiment is strongly bullish with 14 buy ratings and zero sell ratings recorded for the stock.
📉 Technical analysis shows an RSI of 32.16 indicating oversold conditions and a positive MACD crossover suggesting momentum.
🏥 The firm operates through three strategic segments: Health Benefits, CarelonRx, and Carelon Services.
🛡️ Elevance Health maintains a substantial market capitalization of $84.37 billion within the healthcare sector.
Bullish Signals
Analysts target $415.81, offering 7% upside.
14 buy ratings show strong institutional confidence.
Free cash flow exceeds $4.29 billion.
Positive MACD of 5.61 signals bullish momentum.
Forward P/E of 13.28 suggests attractive valuation.
Bullish Signals
Analysts maintain an average target price of $415.81, which represents a 7% upside from the current trading price of $388.50.
The stock has received 14 buy ratings with no sell ratings, indicating strong institutional confidence in future performance.
Free cash flow exceeds $4.29 billion, providing ample liquidity for operations and potential shareholder returns.
Technical indicators show a positive MACD of 5.61 above the signal line, signaling current bullish momentum.
The Relative Strength Index (RSI) is at 32.16, suggesting the stock may be undervalued or approaching a rebound from oversold levels.
A Forward P/E ratio of 13.28 suggests an attractive valuation relative to anticipated future earnings growth.
Elevance Health announced a strategic investment of $640 million in affordable housing initiatives over the past five years, bringing its total nationwide commitment to over $1 billion. This funding supports approximately 400 properties and more than 40,000 housing units across 45 states, the District of Columbia, Puerto Rico, and Guam. The recent phase specifically targets 15 new properties in 10 states, developing 2,654 units including apartments, townhomes, and single-family residences.
The company's initiative is driven by its 'whole health' strategy, which recognizes housing instability as a critical determinant of health outcomes for Medicaid populations. Internal analysis revealed that 43% of members with over 50 emergency room visits annually were experiencing homelessness. By addressing social determinants like housing, Elevance aims to reduce avoidable healthcare utilization, manage chronic conditions better, and lower overall costs.
Beyond development, Elevance Health provides flexible funding programs to assist roughly 1,500 households with rent, utilities, and move-in expenses to prevent eviction. These efforts are integrated with health services, demonstrating strong results where over 90% of participants maintained stable housing six months after receiving support. The company plans to continue expanding these community-based solutions to improve population health at scale.
🏠 Invested $640M in affordable housing, surpassing $1B nationwide commitment.
📊 Supports 40,000 units across 45 states and territories.
📉 43% of high-utilization Medicaid members with 50+ ER visits are homeless.
💰 Flexible funding assisted 1,500 households with rent and deposits.
🩺 Over 90% maintain housing stability six months post-support.
🏠 Elevance Health invested $640 million in affordable housing over the last five years, surpassing a total $1 billion commitment nationwide.
📊 The investment supports approximately 400 properties and more than 40,000 housing units across 45 states and territories.
🏗️ Recent funding covers 15 new properties in 10 states, creating 2,654 affordable units including apartments and single-family homes.
📉 Internal data shows 43% of high-utilization Medicaid members with over 50 ER visits are experiencing homelessness.
💰 Flexible funding programs have assisted approximately 1,500 households by covering rent, utilities, and security deposits.
🤝 Partnerships with community organizations help members access vouchers and prevent evictions effectively.
🩺 Stable housing initiatives show strong results, with over 90% of participants maintaining housing stability six months post-support.
🎯 The strategy targets low-to-moderate income households earning 80% or less of the area median income.
📈 Elevance Health serves approximately 105 million consumers through its diverse portfolio of medical and pharmacy solutions.
🚀 The company plans to continue expanding affordable housing efforts aligned with community needs and health priorities.
Bullish Signals
Elevance Health committed over $1 billion to affordable housing.
$640 million investment created 2,654 new units across 15 properties.
43% of high-utilization homeless patients identified for intervention via housing stability.
Flexible funding assisted ~1,500 households with rent and utilities.
90% success rate in maintaining stable housing six months later.
Bullish Signals
Elevance Health has committed over $1 billion total to affordable housing, demonstrating a significant long-term investment in social determinants of health.
The recent $640 million investment supports the development of 2,654 new units across 15 properties, directly addressing housing shortages.
Internal analysis confirms a direct link between housing stability and reduced healthcare costs, with 43% of high-utilization homeless patients identified for intervention.
Flexible funding programs have successfully assisted approximately 1,500 households in covering essential expenses like rent and utilities to prevent homelessness.
Integrated health and housing support has achieved a 90% success rate in maintaining stable housing six months after receiving assistance.
The initiative targets vulnerable populations including seniors, people with disabilities, and families facing housing insecurity.
Elevance Health is launching a new initiative called Total Movement Care (TMC) to address the growing prevalence of musculoskeletal conditions, which affect three in four adults with chronic issues. This program connects members to MSK-trained clinicians, offers virtual-first physical therapy, and provides guided navigation to specialists. The goal is to enable earlier assessment and coordinated, evidence-based care to improve outcomes and reduce unnecessary procedures.
Beyond the new TMC launch, Elevance Health is expanding its broader strategy for managing chronic conditions through data-driven tools like Proactive Member Engagement (PME) and Concierge Care. PME utilizes advanced analytics on medical and social data to deliver over 12 million interactions annually via text, phone, and email, helping members adhere to medication schedules and attend wellness visits. These efforts aim to create a seamless, personalized experience that reduces fragmentation in care.
The company is also leveraging its digital platform, Sydney Health, to provide real-time guidance tailored to individual member benefits and health history. By surfacing actionable nudges for scheduling appointments and completing screenings, the platform helps translate complex care plans into simple steps. Together with Shantanu Agrawal, MD, Chief Health Officer, these initiatives reflect a commitment to proactive support that helps members stay engaged and confident in managing their long-term health.
🏥 Elevance launches Total Movement Care with virtual-first physical therapy.
📊 Proactive Member Engagement delivers 12 million annual interactions yearly.
💬 Concierge Care offers 24/7 nurse support to reduce hospitalizations.
📱 Sydney Health uses data for personalized digital health nudges.
👥 Company serves 105 million consumers across diverse medical solutions.
🏥 Elevance Health introduces Total Movement Care (TMC), a new musculoskeletal care experience featuring MSK-trained clinicians and virtual-first physical therapy.
📊 The company operates Proactive Member Engagement (PME), an enterprise-wide program delivering over 12 million interactions annually to improve medication adherence and wellness visits.
💬 Concierge Care offers dedicated teams with 24/7 nurse support for members with complex needs, aiming to reduce avoidable emergency room visits and hospitalizations.
📱 Sydney Health provides personalized digital guidance using member data to surface tailored nudges for scheduling appointments and managing conditions.
👥 Elevance Health serves approximately 105 million consumers through a diverse portfolio of medical, pharmacy, behavioral, and clinical solutions.
🎯 The new TMC program is initially available to a subset of members in affiliated fully insured health plans with plans for future expansion.
Bullish Signals
Total Movement Care offers virtual physical therapy for better outcomes.
Proactive Member Engagement scaled to over 12 million interactions.
Concierge Care provides 24/7 nurse support and tailored plans.
Sydney Health uses data to simplify care plans.
Strategy reduces avoidable ER visits through earlier assessment.
Bullish Signals
Elevance Health is launching Total Movement Care (TMC) to provide earlier access to MSK-trained clinicians and virtual-first physical therapy, aiming to improve patient outcomes.
The Proactive Member Engagement (PME) program has already scaled to over 12 million interactions, successfully helping members take action without navigating fragmented communications.
Concierge Care provides 24/7 nurse support and tailored care plans that help members manage side effects and adjust treatments in real-time.
Sydney Health uses member data to deliver clear, actionable prompts that simplify complex care plans and encourage timely engagement with healthcare services.
The company's strategy focuses on reducing avoidable emergency room visits and hospitalizations by enabling earlier assessment and coordinated care.
We use cookies to run the site and, only if you allow it, for live chat, analytics, personalization and ad measurement.
We use cookies to:
Deliver and maintain our services, protect against spam, fraud and abuse
Offer a live chat with our team (Enuchat, optional)
Measure audience engagement and site statistics to understand how our services are used (Google Analytics, optional)
Remember your quiz progress and tailor the knowledge base to your skill level (optional)
Measure how our ads on Facebook and Instagram perform, including whether a visit leads to a confirmed sign-up, matched to your Facebook or Instagram account using hashed contact details you enter (Meta Pixel, optional)
Optional cookies are only set if you allow them. You can accept all, reject all or choose per category, and change your choice at any time via the "Manage Cookies" link in the footer. Google and Meta may process this data in the USA. More in our Privacy Policy.
Manage cookie preferences
Necessary cookiesAlways active
Required for the website to function. These cannot be disabled.
Cookie
Purpose
Duration
PHPSESSID
Session identifier for login, security tokens, and site functionality
Session
cookie_consent
Stores your cookie preferences
1 year
Functional cookies
Show the live chat button so you can message our team. The Enuchat chat widget stores a visitor ID in your browser and sends your chat messages to Enuchat. When this is off, the chat is not loaded.
Cookie
Purpose
Duration
enuchat_visitor_id
Keeps your chat conversation linked to this browser (Enuchat, browser storage)
Until you clear it or turn this off
Analytics cookies
Help us understand how visitors use our website with Google Analytics, provided by Google LLC. Google receives pages visited, device data and an IP address, and may process them in the USA. If you also allow marketing cookies, the Google tag can detect contact details you enter or see on our pages, such as your email address, phone number, name or address, hash them before sending and pass them to Google so it can match your visits to a Google account for measuring our ads. Hashed details are still personal data. See how Google uses information from sites that use its services.
Cookie
Purpose
Duration
_ga
Distinguishes unique visitors (Google Analytics)
2 years
_ga_*
Maintains session state (Google Analytics)
2 years
Personalization cookies
Remember your quiz progress and work out your investing level so we can recommend knowledge-base articles and the right reading depth for you. Stored only on your device.
Cookie
Purpose
Duration
bes_user_level
Your quiz-derived investing level, used to tailor content
1 year
Marketing cookies
Let Meta (Facebook and Instagram) measure how our ads perform, using the Meta Pixel. Meta Platforms Ireland Ltd. receives the pages you visit and, when you confirm the email address of a new account, a "completed registration" event, together with browser identifiers and your IP address. Meta's automatic advanced matching also reads contact details you type into forms on our site, such as your email address or name, hashes them in your browser and sends them with these events so Meta can match them to a Facebook or Instagram account. Hashed details are still personal data. These events are sent from your browser and may also be forwarded to Meta through Meta's Conversions API Gateway. Our own server also sends page visits and completed-registration events directly to Meta's Conversions API, with your IP address, browser user agent and Meta browser identifiers, so Meta can count it once. To help Meta match these visits, your browser and our server also send a random visitor ID from our own cookie and, if you are signed in, your account ID, your confirmed email address and the name, city, postal code and country saved in your profile, all hashed first. We and Meta are joint controllers for collecting and sending this data, and Meta's further use, which may include processing in the USA, is described in the Meta Privacy Policy. When this is off, the Meta Pixel is not loaded and no page visit or registration event is sent to Meta. Together with analytics cookies, this choice also lets Google receive hashed contact details, as described under Analytics cookies.
Cookie
Purpose
Duration
_fbp
Identifies browsers for Meta ad measurement (Meta Pixel)
3 months
_fbc
Stores the Meta ad click that brought you here (Meta Pixel)
3 months
_bes_meid
Random visitor ID, sent to Meta only hashed, so your visits can be matched (Meta Pixel and Conversions API)